[{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alto Neuroscience Emerges with Largest Clinical-Stage Precision Psychiatry Pipeline and $40 Million in Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Cerebral Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cerebral and Alto Neuroscience Enter into Strategic Collaboration to Launch First-Ever Decentralized Study in Precision Psychiatry","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Lightswitch Capital","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alto Neuroscience Announces $35 Million Series B Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alto Neuroscience Presents New Data Leveraging EEG and Machine Learning to Predict Individual Response to Antidepressants at the 61st Annual Meeting of the American College of Neuropsychopharmacology","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alto Neuroscience Announces Positive Data from Phase 1 Study Evaluating Brain Effects of Novel Drug Combinations","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alto Neuroscience Announces Positive Results for ALTO-100 in Phase 2 Study Supporting Advancement of First-in-Class Mechanism for Treating Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alto Neuroscience Announces $60 Million in Additional Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alto Neuroscience Announces Positive Results from Phase 2 Study of ALTO-100 in Post-Traumatic Stress Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"InVivium Capital","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alto Neuroscience Closes $45 Million in Oversubscribed Series C Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alto Neuroscience preps IPO to Push CNS Therapies Through Clinic","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$128.6 million","upfrontCash":"Undisclosed","newsHeadline":"Alto Neuroscience Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$147.9 million","upfrontCash":"Undisclosed","newsHeadline":"Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alto Neuroscience Announces Positive Results from Phase 2 Study of ALTO-300 in Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Alto Neuroscience
ALTO-203 is a novel small molecule histamine H3 receptor inverse agonist, which is being developed for the treatment of patients with MDD and elevated anhedonia.
The net proceeds will be used to advance the clinical development of ALTO-100, targeting brain-derived-neurotrophic-factor (BDNF), which is being developed by Alto Neuroscience for the treatment of major depressive disorder and Post-traumatic stress disorder.
The net proceeds will be used to advance the clinical development of ALTO-100, targeting brain-derived-neurotrophic-factor (BDNF), which is being developed by Alto Neuroscience for the treatment of major depressive disorder and Post-traumatic stress disorder.
The net proceeds will be used to advance the clinical development of ALTO-100, targeting brain-derived-neurotrophic-factor (BDNF) is being developed by Alto Neuroscience for the treatment of major depressive disorder and Post-traumatic stress disorder.
ALTO-300 is an investigational small molecule drug candidate, which is a melatonin receptor agonist. currently, it is being evaluated under clinical development with patients suffering related to major depressive disorder.
The funds will be used to support ongoing and planned clinical development of the Company's late-stage CNS product candidates, including ALTO-100 currently in Phase II for Major Depressive Disorder.
The Phase 2 study leveraged Alto’s Precision Psychiatry Platform™ to identify likely drug responders based on an understanding of biological heterogeneity in depression and ALTO-100’s novel mechanism.
Funding will support Alto through a total of four Phase 2 readouts with four novel drug candidates across three indications, as well as the continued evolution of Alto’s Precision Psychiatry Platform™. ALTO-100 is being developed for Major Depressive Disorder.
The Phase 2 study leveraged Alto’s Precision Psychiatry Platform™ to identify likely drug responders based on an understanding of biological heterogeneity in depression and ALTO-100’s novel mechanism.
Novel drug combinations, ALTO-103 and ALTO-104, exhibited significant pharmacodynamic effects compared to placebo on measures associated with therapeutic response in patients.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
